What medication is recommended for severe vertigo caused by inner‑ear pathology?

Medication for Severe Vertigo from Inner Ear Problems

For acute severe vertigo attacks from inner ear pathology, use a short course of vestibular suppressants—specifically antihistamines (meclizine, dimenhydrinate) or benzodiazepines (diazepam, lorazepam)—only during active attacks, not for chronic prevention. 1

Acute Attack Management

When a patient presents with severe rotational vertigo from inner ear disease, the immediate goal is symptom relief during the attack itself:

First-Line Vestibular Suppressants

• Antihistamines: Meclizine or dimenhydrinate are preferred initial agents
• Benzodiazepines: Diazepam or lorazepam for more severe symptoms
• Duration: Limited course only during attacks—do NOT use chronically 1

Critical caveat: All benzodiazepines carry significant risk for drug dependence, so reserve these for severe cases and limit duration 1. Antihistamines should be tried first in most patients.

Anticholinergics (Less Common)

Centrally acting anticholinergics like scopolamine can suppress acute vertigo but cause problematic side effects (blurred vision, dry mouth, urinary retention, sedation) and have significant toxicity/withdrawal risks when used beyond several days 1. These are not commonly prescribed for inner ear vertigo.

Important Limitations

There is insufficient evidence demonstrating that any specific drug class is superior to another 1. The choice depends on:

• Severity of symptoms (benzodiazepines for more severe)
• Patient tolerance of side effects
• Risk of dependence (favor antihistamines)

Beyond Acute Management

For patients with recurrent vertigo (particularly Ménière's disease):

Preventive Strategies

• Betahistine (histamine analogue): Increases vasodilation to inner ear 1, 2
• Diuretics: Furosemide and spironolactone combination for fluid management 1, 2
• Lifestyle modifications: Low sodium diet (1500-2300 mg daily), limit caffeine and alcohol 1

Recent evidence suggests that combined oral therapy with betahistine plus diuretics (furosemide/spironolactone) provides reliable vertigo control and hearing stabilization in Ménière's disease, offering a non-invasive first-line strategy 2.

Refractory Cases

When medical management fails:

• Intratympanic gentamicin: Achieves 89-95% vertigo control but carries 8-20% risk of hearing loss 3, 4, 5
• Intratympanic dexamethasone: May help vertigo without hearing risk 6
• Surgical options: Reserved for truly intractable cases 3

Key Clinical Pitfalls

1. Don't use vestibular suppressants chronically—they delay central compensation and worsen long-term outcomes
2. Confirm true vertigo (rotational spinning sensation) versus lightheadedness before prescribing 1
3. Rule out central causes (stroke, tumor) before attributing symptoms to inner ear—especially if vertigo lasts >24 hours without hearing symptoms 1
4. Avoid benzodiazepines as first-line due to dependence risk 1

Diagnostic Considerations

Before prescribing, distinguish inner ear vertigo from mimics:

• BPPV: Seconds-long positional vertigo (treat with repositioning maneuvers, not medications) 1, 7
• Vestibular neuritis: Prolonged vertigo (12-36 hours) without hearing loss 1
• Vestibular migraine: Variable duration attacks, often with migraine history 1, 8
• Stroke: Persistent symptoms with neurologic signs 1

The structured approach ensures appropriate medication use while avoiding overtreatment and recognizing when vestibular suppressants are inappropriate.